111 related articles for article (PubMed ID: 30865722)
1. Incidence of and risk factors for medical care interruption in people living with HIV in recent years.
Fournier AL; Yazdanpanah Y; Verdon R; Lariven S; Mackoumbou-Nkouka C; Phung BC; Papot E; Parienti JJ; Landman R; Champenois K
PLoS One; 2019; 14(3):e0213526. PubMed ID: 30865722
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors for medical care interruption in people living with HIV in a French provincial city.
Fournier AL; Parienti JJ; Champenois K; Feret P; Papot E; Yazdanpanah Y; Verdon R
PLoS One; 2020; 15(10):e0240417. PubMed ID: 33057366
[TBL] [Abstract][Full Text] [Related]
3. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
4. HIV medical care interruption among people living with HIV in Spain, 2004-2020.
Izquierdo R; Rava M; Moreno-García E; Blanco JR; Asensi V; Cervero M; Curran A; Rubio R; Iribarren JA; Jarrín I;
AIDS; 2023 Jul; 37(8):1277-1284. PubMed ID: 36939068
[TBL] [Abstract][Full Text] [Related]
5. HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV.
Guiguet M; Furco A; Tattevin P; Costagliola D; Molina JM;
HIV Med; 2007 Mar; 8(2):124-30. PubMed ID: 17352769
[TBL] [Abstract][Full Text] [Related]
6. Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women.
Konopnicki D; Manigart Y; Gilles C; Barlow P; de Marchin J; Feoli F; Larsimont D; Delforge M; De Wit S; Clumeck N
J Infect Dis; 2013 Jun; 207(11):1723-9. PubMed ID: 23463709
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France.
Breton G; Lewden C; Spire B; Salmon D; Brun-Vézinet F; Duong M; Allavena C; Leport C; Salamon R;
HIV Med; 2007 Apr; 8(3):164-70. PubMed ID: 17461860
[TBL] [Abstract][Full Text] [Related]
8. Incidence rate and risk factors for loss to follow-up in HIV-infected patients from five French clinical centres in Northern France - January 1997 to December 2006.
Ndiaye B; Ould-Kaci K; Salleron J; Bataille P; Bonnevie F; Choisy P; Cochonat K; Fontier C; Guerroumi H; Ajana F; Chaud P; Yazdanpanah Y
Antivir Ther; 2009; 14(4):567-75. PubMed ID: 19578242
[TBL] [Abstract][Full Text] [Related]
9. Later cART initiation in migrant men from sub-Saharan Africa without advanced HIV disease in France.
de Monteynard LA; Dray-Spira R; de Truchis P; Grabar S; Launay O; Meynard JL; Khuong-Josses MA; Gilquin J; Rey D; Simon A; Pavie J; Mahamat A; Matheron S; Costagliola D; Abgrall S;
PLoS One; 2015; 10(3):e0118492. PubMed ID: 25734445
[TBL] [Abstract][Full Text] [Related]
10. Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain.
Monge S; Alejos B; Dronda F; Del Romero J; Iribarren JA; Pulido F; Rubio R; Miró JM; Gutierrez F; Del Amo J;
HIV Med; 2013 May; 14(5):273-83. PubMed ID: 23171059
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for loss to follow-up prior to ART initiation among patients enrolling in HIV care with CD4+ cell count ≥200 cells/μL in the multi-country MTCT-Plus Initiative.
Gwynn RC; Fawzy A; Viho I; Wu Y; Abrams EJ; Nash D
BMC Health Serv Res; 2015 Jun; 15():247. PubMed ID: 26108273
[TBL] [Abstract][Full Text] [Related]
12. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
Mocroft A; Staszewski S; Weber R; Gatell J; Rockstroh J; Gasiorowski J; Panos G; Monforte Ad; Rakhmanova A; Phillips AN; Lundgren JD;
Antivir Ther; 2007; 12(3):325-33. PubMed ID: 17591022
[TBL] [Abstract][Full Text] [Related]
13. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
[TBL] [Abstract][Full Text] [Related]
14. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
[TBL] [Abstract][Full Text] [Related]
15. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
Seminari E; De Silvestri A; Boschi A; Tinelli C
AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
[TBL] [Abstract][Full Text] [Related]
16. Elevated risk of viral rebound on ART in migrants living in France: role of socioeconomic factors.
Abgrall S; Raho-Moussa M; Seng R; Ghislain M; Matheron S; Pialoux G; Goujard C; Meyer L;
Antivir Ther; 2019; 24(7):541-552. PubMed ID: 31868654
[TBL] [Abstract][Full Text] [Related]
17. Predictors of dropout from care among HIV-infected patients initiating antiretroviral therapy at a public sector HIV treatment clinic in sub-Saharan Africa.
Asiimwe SB; Kanyesigye M; Bwana B; Okello S; Muyindike W
BMC Infect Dis; 2016 Feb; 16():43. PubMed ID: 26832737
[TBL] [Abstract][Full Text] [Related]
18. Travel-related health events and their risk factors in HIV-infected sub-Saharan migrants living in France and visiting their native country: The ANRS VIHVO cohort study.
Pistone T; Ouattara E; Gabillard D; Lele N; Duvignaud A; Cordel H; Malvy D; Bouchaud O; Abgrall S;
Travel Med Infect Dis; 2019; 29():40-47. PubMed ID: 30951905
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy.
Gotti D; Danesi M; Calabresi A; Ferraresi A; Albini L; Donato F; Castelli F; Scalzini A; Quiros-Roldan E;
AIDS Patient Care STDS; 2013 May; 27(5):259-65. PubMed ID: 23600703
[TBL] [Abstract][Full Text] [Related]
20. Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial.
Rosen S; Maskew M; Fox MP; Nyoni C; Mongwenyana C; Malete G; Sanne I; Bokaba D; Sauls C; Rohr J; Long L
PLoS Med; 2016 May; 13(5):e1002015. PubMed ID: 27163694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
